AU2012271845B2 - Anti-PSGL-1 antibodies and uses thereof - Google Patents

Anti-PSGL-1 antibodies and uses thereof Download PDF

Info

Publication number
AU2012271845B2
AU2012271845B2 AU2012271845A AU2012271845A AU2012271845B2 AU 2012271845 B2 AU2012271845 B2 AU 2012271845B2 AU 2012271845 A AU2012271845 A AU 2012271845A AU 2012271845 A AU2012271845 A AU 2012271845A AU 2012271845 B2 AU2012271845 B2 AU 2012271845B2
Authority
AU
Australia
Prior art keywords
antibody
seq
amino acid
psgl
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012271845A
Other languages
English (en)
Other versions
AU2012271845A1 (en
Inventor
Stefan Bassarab
Barbara Enenkel
Patrick Garidel
Tobias Litzenburger
Heidrun SCHOTT
Sanjaya Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altrubio Inc
Original Assignee
Altrubio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012271845(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Altrubio Inc filed Critical Altrubio Inc
Publication of AU2012271845A1 publication Critical patent/AU2012271845A1/en
Assigned to ABGENOMICS COOPERATIEF U.A. reassignment ABGENOMICS COOPERATIEF U.A. Amend patent request/document other than specification (104) Assignors: ABGENOMICS COOPERATIEF U.A.
Application granted granted Critical
Publication of AU2012271845B2 publication Critical patent/AU2012271845B2/en
Assigned to ALTRUBIO INC. reassignment ALTRUBIO INC. Request for Assignment Assignors: ABGENOMICS COOPERATIEF U.A.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2012271845A 2011-06-13 2012-06-12 Anti-PSGL-1 antibodies and uses thereof Active AU2012271845B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161496249P 2011-06-13 2011-06-13
US61/496,249 2011-06-13
PCT/US2012/042068 WO2012174001A1 (en) 2011-06-13 2012-06-12 Anti-psgl-1 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2012271845A1 AU2012271845A1 (en) 2014-01-23
AU2012271845B2 true AU2012271845B2 (en) 2017-07-27

Family

ID=47357432

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012271845A Active AU2012271845B2 (en) 2011-06-13 2012-06-12 Anti-PSGL-1 antibodies and uses thereof

Country Status (21)

Country Link
US (4) US20130209449A9 (OSRAM)
EP (2) EP2718325A4 (OSRAM)
JP (1) JP6180408B2 (OSRAM)
KR (1) KR102103036B1 (OSRAM)
CN (3) CN108892726A (OSRAM)
AU (1) AU2012271845B2 (OSRAM)
BR (1) BR112013031892A2 (OSRAM)
CA (1) CA2838952C (OSRAM)
CL (1) CL2013003570A1 (OSRAM)
CO (1) CO6940376A2 (OSRAM)
EC (1) ECSP14013132A (OSRAM)
IL (2) IL229844B (OSRAM)
MX (1) MX358447B (OSRAM)
NZ (1) NZ619524A (OSRAM)
PH (1) PH12013502568B1 (OSRAM)
RU (1) RU2650817C2 (OSRAM)
SG (1) SG10201604767TA (OSRAM)
TW (1) TWI643872B (OSRAM)
UA (1) UA114712C2 (OSRAM)
WO (1) WO2012174001A1 (OSRAM)
ZA (1) ZA201400209B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
UA105492C2 (uk) 2004-05-11 2014-05-26 Абдженомікс Коеператіеф У.А. Спосіб одержання антитіла для викликання смерті активованих т-клітин, спосіб визначення прийнятної сполуки для викликання смерті активованих т-клітин та фармацевтична композиція
JP6180408B2 (ja) 2011-06-13 2017-08-16 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
CN106659784B (zh) * 2014-07-08 2022-03-29 桑福德伯纳姆医学研究所 Psgl-1调控剂及其用途
ES2880731T3 (es) * 2016-01-08 2021-11-25 Altrubio Inc Anticuerpos anti-PSGL-1 tetravalentes y usos de los mismos
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
TW202421659A (zh) * 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI856437B (zh) 2017-01-20 2024-09-21 法商賽諾菲公司 抗TGF-β抗體及其用途
PE20191708A1 (es) 2017-03-14 2019-11-28 Five Prime Therapeutics Inc ANTICUERPOS DE UNION A VISTA A pH ACIDO
KR20250154550A (ko) 2018-03-21 2025-10-28 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
JP7700036B2 (ja) 2018-07-11 2025-06-30 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡと結合する抗体
MX2021000786A (es) 2018-07-20 2021-06-15 Pf Medicament Receptor para supresor de ig del dominio v de activación de células t (vista).
US20220396632A1 (en) * 2019-06-04 2022-12-15 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell infalmmatory phenotypes and uses thereof
AU2021275499A1 (en) * 2020-05-22 2022-11-24 Formycon Ag Ace2-fc fusion proteins and uses thereof
CN113667015B (zh) * 2021-08-20 2022-10-11 北京康特泊瑞生物医药科技股份公司 靶向psgl-1蛋白的抗体及其用途
CN118696059A (zh) * 2021-11-17 2024-09-24 美国全心医药生技股份有限公司 使用抗psgl-1抗体与jak抑制剂的组合治疗t细胞介导的炎症性疾病或癌症的方法
AU2023343549A1 (en) * 2022-09-13 2025-03-20 Tetherex Pharmaceuticals Corporation Antibodies, compositions, and methods of treatment
WO2025106784A1 (en) * 2023-11-17 2025-05-22 Altrubio Inc. Anti-psgl-1 antibodies and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563441B2 (en) * 2004-04-13 2009-07-21 Hoffman-La Roche Inc. Anti-P-selectin antibodies
US7604800B2 (en) * 2004-05-10 2009-10-20 AbGenomics Coöperatief U.A. Anti-PSGL-1 antibodies
WO2010070346A2 (en) * 2008-12-18 2010-06-24 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ra) - 836
WO2010102792A2 (en) * 2009-03-12 2010-09-16 Imed Ab Human antibodies against human fas and their use
WO2011014438A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5378464A (en) 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5709859A (en) 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6309639B1 (en) 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5972625A (en) 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
ATE179210T1 (de) 1992-03-17 1999-05-15 Novartis Erfind Verwalt Gmbh Gentechnologisch hergestellte antikörper
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994014836A1 (en) 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
DK0689599T3 (da) 1993-01-25 1999-08-16 Dana Farber Cancer Inst Inc Kimære selectiner ved udveksling af domæner og anvendelser deraf
WO1995014787A1 (en) 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
KR100523506B1 (en) 1995-08-03 2005-10-24 Peptide and O-glycan inhibitors of selectin mediated inflammation
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
WO1999043353A2 (en) 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
BR9914957A (pt) 1998-10-30 2001-07-24 Genetics Inst Inibição de células t citotóxicas por antagonistas de ligando de selectina-p (psgl)
AU3672800A (en) 1999-04-09 2000-11-14 Kyowa Hakko Kogyo Co. Ltd. Method for controlling the activity of immunologically functional molecule
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
AU2001261735B2 (en) 2000-05-19 2006-09-21 The Center For Blood Research, Inc. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
EP1325123A4 (en) 2000-09-12 2004-07-21 Inst Genetics Llc INHIBITION OF STENOSIS OR RESTENOSIS USING P-SELECTINE ANTAGONISTS
CA2433225A1 (en) 2000-12-29 2002-07-11 Bio-Technology General, Inc. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040002450A1 (en) 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US6884619B2 (en) 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
JP2005536199A (ja) 2002-07-01 2005-12-02 サビエント ファーマシューティカルズ，インコーポレイティド 抗体及びそれらの使用
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
KR20060107501A (ko) 2003-06-30 2006-10-13 바이오-테크널러지 제너럴 (이스라엘) 리미티드 특이적인 인간 항체
DK1707627T3 (da) * 2003-12-25 2012-12-17 Kyowa Hakko Kirin Co Ltd Antagonistisk anti-CD40-antistofmutant.
EP1720996A4 (en) * 2004-02-13 2007-03-21 Immunomedics Inc RECOMBINANT CYTOTOXIC RASES CONTAINING FUSION PROTEINS
UA105492C2 (uk) 2004-05-11 2014-05-26 Абдженомікс Коеператіеф У.А. Спосіб одержання антитіла для викликання смерті активованих т-клітин, спосіб визначення прийнятної сполуки для викликання смерті активованих т-клітин та фармацевтична композиція
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
TWI551607B (zh) * 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
NZ580553A (en) * 2007-03-22 2012-05-25 Genentech Inc Apoptotic anti- ige antibodies binding the membrane-bound ige
ES2667863T3 (es) * 2007-03-29 2018-05-14 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
JP6071165B2 (ja) * 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US9273134B2 (en) 2007-06-05 2016-03-01 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
CN101842117A (zh) * 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 抗igf-1r抗体及其用途
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20110086366A1 (en) * 2008-02-22 2011-04-14 Genmab A/S Methods for assessing the risk of adverse events upon treatment with igg4 antibodies
WO2009140623A2 (en) * 2008-05-15 2009-11-19 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
JP6180408B2 (ja) 2011-06-13 2017-08-16 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
KR20170063507A (ko) 2014-06-20 2017-06-08 어브게노믹스 인터내셔널 인코포레이티드 Her2 항체-약물 접합체

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563441B2 (en) * 2004-04-13 2009-07-21 Hoffman-La Roche Inc. Anti-P-selectin antibodies
US7604800B2 (en) * 2004-05-10 2009-10-20 AbGenomics Coöperatief U.A. Anti-PSGL-1 antibodies
WO2010070346A2 (en) * 2008-12-18 2010-06-24 Medimmune Limited BINDING MEMBERS FOR INTERLEUKIN-4 RECEPTOR ALPHA (IL-4Ra) - 836
WO2010102792A2 (en) * 2009-03-12 2010-09-16 Imed Ab Human antibodies against human fas and their use
WO2011014438A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AALBERSE R. et al, lgG4 breaking the rules, Immunology, 2002, Vol. 105(1), pp 9-19 *
ANGAL S. et al, A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (lgG4) antibody, Molecular Immunology, 1993, Vol. 30(1), pp 105-108 *
LABRIJN A. et al, Therapeutic lgG4 antibodies engage in Fab-arm exchange with endogenous human lgG4 in vivo, Nature Biotechnology, 2009, Vol. 27(8), pp 767-771 *
STUBENRAUCH K. et al, Impact of Molecular Processing in the Hinge Region of Therapeutic lgG4 Antibodies on Disposition Profiles in Cynomolgus Monkeys, Drug Metabolism and Disposition, 2010, Vol. 38(1), pp 84-91 *
VAN DER NEUT KOLFSCHOTEN M. et al, Anti-inflammatory activity of human lgG4 antibodies by dynamic Fab arm exchange, Science, 2007, Vol. 317(5844), pp 1554-1557 *

Also Published As

Publication number Publication date
EP2718325A4 (en) 2015-03-11
US20130251708A1 (en) 2013-09-26
PH12013502568B1 (en) 2018-08-10
IL229844B (en) 2022-02-01
KR102103036B1 (ko) 2020-04-22
KR20140066153A (ko) 2014-05-30
EP2718325A1 (en) 2014-04-16
US20130011391A1 (en) 2013-01-10
RU2013158083A (ru) 2015-09-20
SG10201604767TA (en) 2016-08-30
US20130209449A9 (en) 2013-08-15
JP2014519524A (ja) 2014-08-14
ZA201400209B (en) 2020-05-27
WO2012174001A1 (en) 2012-12-20
US20240124604A1 (en) 2024-04-18
PH12013502568A1 (en) 2014-01-27
UA114712C2 (uk) 2017-07-25
CN108892726A (zh) 2018-11-27
JP6180408B2 (ja) 2017-08-16
ECSP14013132A (es) 2015-04-30
CN116063522A (zh) 2023-05-05
CA2838952A1 (en) 2012-12-20
AU2012271845A1 (en) 2014-01-23
CN103732626A (zh) 2014-04-16
IL287270A (en) 2021-12-01
TW201302791A (zh) 2013-01-16
US20210395383A1 (en) 2021-12-23
MX358447B (es) 2018-08-21
CL2013003570A1 (es) 2014-08-22
US11897964B2 (en) 2024-02-13
MX2013014814A (es) 2014-07-22
EP3925978A1 (en) 2021-12-22
CO6940376A2 (es) 2014-05-09
CA2838952C (en) 2020-11-24
BR112013031892A2 (pt) 2016-11-22
NZ619524A (en) 2016-10-28
TWI643872B (zh) 2018-12-11
RU2650817C2 (ru) 2018-04-17

Similar Documents

Publication Publication Date Title
US11897964B2 (en) Anti-PSGL-1 antibodies and uses thereof
US11897957B2 (en) Anti-ILT4 antibodies and antigen-binding fragments
US20250092151A1 (en) Tetravalent anti-psgl-1 antibodies and uses thereof
AU2020365021A1 (en) PD1 and VEGFR2 dual-binding agents
KR20230086809A (ko) 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
AU2016246152A9 (en) Interleukin-2 muteins for the expansion of T-regulatory cells
HK40065237A (en) Anti-psgl-1 antibodies and uses thereof
RU2782950C2 (ru) Подкожное введение анти-cd38 антител
HK40075900A (en) Pd1 and vegfr2 dual-binding agents
HK40075900B (en) Pd1 and vegfr2 dual-binding agents
NZ621619A (en) Caninised tumour necrosis factor antibodies and methods of using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALTRUBIO INC.

Free format text: FORMER OWNER(S): ABGENOMICS COOPERATIEF U.A.